Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs Detemir in T2DM (L2T3)
NCT00405418Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2006
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients reaching HbA1c < 7% without symptomatic hypoglycemia at 24 weeks. Started Nov 2006; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00405418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405418.